01—Abstract
Summary
Summary of the 8-K filed January 8, 2025. Cited figures are marked; the original filing is the authoritative source.
Labcorp Holdings Inc. (NYSE: LH) filed this Form 8-K on January 8, 2025 under Item 7.01 (Regulation FD Disclosure) to announce the timing of its fourth-quarter 2024 financial results.
The company will release those results before the market opens on Thursday, February 6, 2025, and will host a conference call and webcast at 9 a.m. ET that day to discuss them. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website.
The filing contains no financial results, guidance, or operating metrics for the period. Its substance is logistical: it establishes the date and format of the Q4 2024 earnings event for investors and analysts. A replay of the webcast will be available approximately two hours after the live event and will remain accessible until January 24, 2026.
The filing attaches Exhibit 99.1, a press release dated January 8, 2025, which carries the same earnings-date announcement. The company describes itself as a global leader in laboratory services, with more than 67,000 employees serving clients in approximately 100 countries, and notes it supported 84%a of new drugs and therapeutic products approved by the FDA in 2023.
02—Key points
Key Highlights
- Labcorp will report Q4 2024 financial results before market open on Thursday, February 6, 2025.
- A conference call and webcast will begin at 9 a.m. ET on February 6, 2025, listen-only for participants.
- The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website.
- A webcast replay will be available about two hours after the live event and until January 24, 2026.
- The filing is a Regulation FD disclosure under Item 7.01 and contains no financial results or guidance.
- Exhibit 99.1 is a January 8, 2025 press release announcing the earnings date.
- Labcorp reports more than 67,000 employees serving clients in approximately 100 countries and supported 84% of FDA new drug and therapeutic approvals in 2023.
03—Questions
Frequently Asked Questions
When will Labcorp report its fourth-quarter 2024 results?
Labcorp will release its fourth-quarter 2024 financial results before the market opens on Thursday, February 6, 2025.
How can investors access the earnings call?
The conference call and webcast begin at 9 a.m. ET on February 6, 2025, and are webcast live on the Labcorp Investor Relations website. Participants may register on the site to receive dial-in numbers and a PIN; the call is listen-only.
Will the earnings materials be available if I cannot attend the live call?
Yes. A replay of the webcast will be available approximately two hours after the live event conclusion and will remain available until January 24, 2026, on the Labcorp Investor Relations website.
Does this filing include Labcorp's fourth-quarter 2024 financial results?
No. The filing only announces the timing and format of the release. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website on the release date.
Why did Labcorp file this 8-K?
The filing was made under Item 7.01 (Regulation FD Disclosure) to publicly announce the earnings release date and call details, and it attaches a press release dated January 8, 2025 (Exhibit 99.1) with the same information.
04—Continue